---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-059464"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2025-06-13T23:59:59+00:00"
generated_at: "2026-05-19T07:51:20.202752+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Iovance CFO Jean-Marc Bellemin resigns effective July 10, 2025

## Summary
- Jean-Marc Bellemin, CFO and principal financial & accounting officer, resigns effective July 10, 2025.
- No replacement named; company states departure is to pursue other opportunities.
- Frederick G. Vogt serves as Interim CEO and President; CFO role remains unfilled.

## SEC filing metadata
- accession: 0001104659-25-059464
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2025-06-13T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465925059464/0001104659-25-059464-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465925059464/tm2517988d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-059464
- JSON: https://secwatch.observer/filing/0001104659-25-059464.json
- Plain text: https://secwatch.observer/filing/0001104659-25-059464.txt

## Key facts
- Executive change
  Jean-Marc Bellemin resigned as Chief Financial Officer at IOVANCE BIOTHERAPEUTICS, INC..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On June 10, 2025, Jean-Marc Bellemin, the Chief Financial Officer and principal financial and accounting officer of Iovance Biotherapeutics, Inc. (the “Company”), provided the Company with written notice under his Executive Employment Agreement, dated November 23, 2020, that he would resign from the Company, effective July 10, 2025, to pursue other opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465925059464/0001104659-25-059464-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.